Company intelligence / Profile preview

Ribonexus

Villejuif, France

Ownership: Private
Development stage: Other

Overview

Developing small molecule inhibitors of eIF4A to overcome resistance to targeted therapies in cancer; licensed from Pierre Fabre with pre-clinical support ongoing

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

RBX0901

Preclinical

Partnerships

Pierre Fabre (exclusive license agreement for eIF4A small molecules, including milestones, royalties, pharmacology, and chemistry support)Bpifrance (deep tech financing)

Beyond the preview

Go deeper on Ribonexus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribonexus.

Explore the full profile